Pharmacokinetics of polatuzumab vedotin in combination with R/G-CHP in patients with B-cell non-Hodgkin lymphoma

PURPOSE: The phase Ib/II open-label study (NCT01992653) evaluated the antibody-drug conjugate polatuzumab vedotin (pola) plus rituximab/obinutuzumab, cyclophosphamide, doxorubicin, and prednisone (R/G-CHP) as first-line therapy for B-cell non-Hodgkin lymphoma (B-NHL). We report the pharmacokinetics...

Descripción completa

Detalles Bibliográficos
Autores principales: Shemesh, Colby S., Agarwal, Priya, Lu, Tong, Lee, Calvin, Dere, Randall C., Li, Xiaobin, Li, Chunze, Jin, Jin Y., Girish, Sandhya, Miles, Dale, Lu, Dan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7188703/
https://www.ncbi.nlm.nih.gov/pubmed/32222808
http://dx.doi.org/10.1007/s00280-020-04054-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7188703/
https://www.ncbi.nlm.nih.gov/pubmed/32222808
http://dx.doi.org/10.1007/s00280-020-04054-8

Ejemplares similares